A Multicentre, Randomised, Double-blind, Active-Controlled, 2-arm Parallel-group Treatment, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
Latest Information Update: 29 Apr 2025
At a glance
- Drugs Dapagliflozin (Primary) ; Dapagliflozin/zibotentan (Primary)
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms ZODIAC
- Sponsors AstraZeneca
Most Recent Events
- 29 Apr 2025 New trial record